Purification and Further Characterization of Antithrombin III Milano: Lack of Reactivity with Thrombin

Summary

The functional abnormality of Antithrombin III “Milano”, a previously described variant with monomeric and dimeric forms of abnormal AT III, has been further characterized. Affinity chromatography on heparin-Sepharose led to the separation and purification of two distinct tractions: fraction I is identical to normal AT III; fraction II (abnormal AT III) reproduces the abnormalities of the AT III “Milano”, i.e. lack of thrombin inhibition, incieased mobility by two-dimensional immunoclectrophoresis in the absence of heparin and migration as two bands with molecular weights of 60 K and 120 K by sodium dodecyl sulfate polyaeiylamide gel electrophoresis (SDS-PAGE). The interaction of both fiactions with purified u-thrombin was studied by the formation of complexes as well as by affinity chromatography on thrombin Seplmiose. No thrombin-AT III complexes could be demonstrated with either the monomeric or dimeric forms of purified variant AT III at both concentrations of thrombin used. Similarly, no binding to thrombin-Sepharose was observed, thus indicating that the molecular defect of AT III Milano is related to its absence of reactivity with thrombin.

Keywords

Antithrombin III - Variant - Thrombin binding site

• References

• 1 Wolf M, Boyer C, Tripodi A, Meyer D, Larrieu MJ, Mannucci PM. Antithrombin Milano: A new variant with monomeric and dimeric inactive antithrombin III. Blood 1985; 65: 496-500
• 2 Sas G, Blasko Gy, Banhegyi D, Jako J, Palos LA. Abnormal antithrombin III (antithrombin III “Budapest”) as a cause of a familial thrombophilia. Thromb Diath Haemorrh 1974; 32: 105-115
• 3 Tran TH, Bounameaux H, Bondeli C, Honkanen H, Marbet GA, Duckert F. Purification and partial characterisation of a hereditary abnormal antithrombin III fraction of a patient with recurrent thrombophlebitis. Thromb Haemostas 1980; 44: 87-91
• 4 Wolf M, Boyer C, Lavergne JM, Larrieu MJ. A new familial variant of antithrombin III: “Antithrombin III Paris”. Br J Haematol 1982; 51: 285-295
• 5 Sakuragawa N, Takahashi K, Kondo SI, Koide T. Antithrombin III Toyama: a hereditary abnormal antithrombin III of a patient with recurrent thrombophlebitis. Thromb Res 1983; 31: 305-317
• 6 Girolami A, Fabris F, Cappellato G, Sainati L, Boeri G. Antithrombin III (AT III) Padua 2: A new congenital abnormality with defective heparin cofactor activities but no thrombotic disease. Blut 1983; 47: 93-103
• 7 Chasse JF, Esnard F, Guitton JD, Mouray H, Perigois F, Fauconneau G, Gauthier F. An abnormal plasma antithrombin with no apparent affinity for heparin. Thromb Res 1984; 34: 297-302
• 8 Fischer AM, Cornu P, Sternberg C, Meriane F, Dautzenberg MD, Chafa O, Beguin S, Desnos M. Antithrombin III Alger: A new homozygous AT III variant. Thromb Haemostas 1986; 55: 218-221
• 9 Boyer C, Wolf M, Vedrenne J, Meyer D, Larrieu MJ. Homozygous variant of Antithrombin III: AT III Fontainebleau. Thromb Haemostas 1986; 56: 18-22
• 10 Sorensen PJ, Sas G, Peto I, Blasko Gy, Kremmer T, Samu A. Distinction of two pathologic antithrombin III molecules: antithrombin III “Aalborg” and antithrombin III “Budapest”. Thromb Res 1982; 26: 211-219
• 11 Barbui T, Finazzi G, Rodeghiero F, Dini E. Immunoelectrophoresis evidence of a thrombin-induced abnormality in a new variant of hereditary dysfunctional antithrombin III (AT III “Vicenza”). Br J Haematol 1983; 54: 561-565
• 12 Jorgensen M, Petersen LC, Thorsen S. Purification and characterization of hereditary abnormal antithrombin III with impaired thrombin binding. J Lab Clin Med 1984; 104: 245-256
• 13 Girolami A, Marafiotti F, Rubertelli M, Vicarioto MA, Cappellato G, Mazzuccato M. Antithrombin III Trento, a “new” congenital AT III abnormality with a peculiar crossed-immunoelectrophoretic pattern in the absence of heparin. Acta Haemat 1984; 72: 73-82
• 14 Aiach M, Nora M, Fiessinger JN, Roncato M, Francois D, Alhenc Gelas M. A functional abnormal antithrombin III (AT III) deficiency: AT III Charleville. Thromb Res 1985; 39: 559-570
• 15 Howarth DJ, Samson D, Stirling Y, Seghatchian MJ. Antithrombin III “Northwick Park”: a variant antithrombin with normal affinity for heparin but reduced heparin cofactor activity. Thromb Haemostas 1985; 53: 314-319
• 16 lripodi A, Krachmalnicoff A, Mannucci PM. Characterization of an abnormal antithrombin (Milano 2) with defective thrombin binding. Thromb Haemostas 1986; 56: 349-352
• 17 Sembrano JE, Jacobson JL, Reeve EB, Manco-Johnson MI, Hathaway WE. Abnormal antithrombin III with defective serine- protease binding (Antithrombin III “Denver”). J Clin Invest 1986; 77: 887-893
• 18 Bauer KA, Ashenhurst JB, Chediak J, Rosenberg RD. Antithrombin “Chicago”. A functionally abnormal molecule with increased heparin affinity causing familial thrombophilia. Blood 1983; 62: 1242-1250
• 19 Tengborn L, Frohm B, Nilsson LE, Nilsson IM. A Swedish family with abnormal antithrombin.111. Scand J Haematol 1985; 34: 412-416
• 20 Murayama H, Matsuda M. Abnormal properties and behaviors of antithrombin III found in a thrombophilic patient: defective biological functions and dissimilar antigenic determinants. Thromb Haemostas 1986; 56: 165-171
• 21 Fenton JW, Fasco MJ, Stackrom AB. Human thrombins. Production evaluation and properties of a-thrombin. J Biol Chem 1977; 252: 3587-3599
• 22 Laemmli UK. Cleavage of structural proteins S during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685
• 23 McKay EJ. A simple two-step procedure for the isolation of antithrombin III from biological fluids. Thromb Res 1981; 21: 375-382
• 24 March SC, Parikh I, Cuatrecasas P. A simplified method for cyanogen bromide activation of agarose affinity chromatography. Anal Biochem 1974; 60: 149-152
• 25 Miller-Andersson M, Borg H, Andersson LO. Purification of antithrombin III by affinity chromatography. Thromb Res 1974; 5: 439-452
• 26 Bjork I, Danielsson A, Fenton JW, Jornwall J. The site in human antithrombin for functional proteolytic cleavage by human thrombin. FEBS Lett 1981; 126: 497-502
• 27 Rosenberg RD, Damus PS. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 1975; 248: 6490-6505
• 28 Stephens AW, Thalley BS, Hirs CH. Antithrombin III “Denver”, a reactive site variant. J Biol Chem 1987; 262: 1044-1048
• 29 Devray-Kisuk R, Prochownik EV, Chui D HK, Blajchman MA. Molecular pathology of a mutant antithrombin III gene, AT III “Hamilton”. Blood 1986; 68: 345 (abstr.)